Supplement figures and figure legends




Figure. S1 HBsAg level in serum of AAVS1 mice injected with pAAV plasmid carried different genotypes HBV. Genotype A (pAAV-HBV48), Genotype B (pAAV -C4371), Genotype C (pAAV -Y1021), Genotype D (pAAV -Y10), n=8, all male, for each group.




Figure. S2 Anti-HBs level in mice serum. The 4 different strains of mice were injected with pAAV-HBV and pAAV inject AAVS1 mice as control. Serum anti-HBs level were detected at 30 days post injection, n=8, all male, for each group.




Figure. S3 Remained plasmid DNA in serum of HDI AAVS1 mice. 5 groups of AAVS1 mice. Bleed and detect HBV DNA in mice serum at different time-poits before or in the 24 after injection of pAAV-HBV, n=6, all male, for each group.




Figure. S4 Percentage of mice with persisted viremia in a bigger group. (A) HBsAg level of 30 male AAVS1 mice after injection of pAAV-HBV. 28 of 30 mice sustained expression of HBsAg in the 26 weeks post injection. (B) Percentage of HBsAg positive mice at 26 weeks after injection. P= HBsAg positive mice (serum HBsAg level>10 IU/mL), N= HBsAg negative mice (serum HBsAg level<10 IU/mL).